Jim Cramer Blesses a Caller’s Speculative Investment in Xeris Biopharma

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) was among the stocks Jim Cramer commented on, saying that tech stocks cannot be trusted to lead anymore. When a caller mentioned that XERS is their speculative investment, Cramer said:

I know it because it’s injectables… But I will tell you this: that’s precisely what I want you to do. That’s precisely what you need. But one of them, just one that takes care of all the jonesing you’re doing with speculation. None of that 2, 3x, and the leverage and stuff. Just one spec will do it for you. I like that attitude.

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) develops therapies for chronic endocrine and neurological diseases, including treatments for severe hypoglycemia, primary periodic paralysis, and endogenous hypercortisolemia. In addition, it is developing a once-weekly subcutaneous injection for hypothyroidism, which is currently undergoing a phase 3 clinical trial.

While we acknowledge the risk and potential of XERS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than XERS and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1